Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 10, 2013 08:00 ET | Source: Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals to Announce Third-Quarter 2013 Financial Results on Wednesday, October 30

CAMBRIDGE, Mass., Oct. 10, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative,...
October 07, 2013 08:00 ET | Source: Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program

CAMBRIDGE, Mass., Oct. 7, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative,...
September 26, 2013 08:00 ET | Source: Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals Announces Presentation at the Leerink Swann Rare Disease Roundtable

CAMBRIDGE, Mass., Sept. 26, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel...
September 24, 2013 08:00 ET | Source: Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals Observes Familial Hypercholesterolemia Awareness Day

CAMBRIDGE, Mass., Sept. 24, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel...
September 09, 2013 08:30 ET | Source: Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals' Lomitapide Receives Orphan Drug Designation in Japan for the Treatment of Homozygous Familial Hypercholesterolemia

CAMBRIDGE, Mass., Sept. 9, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of novel, life-altering...
September 06, 2013 08:00 ET | Source: Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program

CAMBRIDGE, Mass., Sept. 6, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative,...
September 05, 2013 08:00 ET | Source: Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals Announces Presentation at the Morgan Stanley Global Healthcare Conference

CAMBRIDGE, Mass., Sept. 5, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel...
August 06, 2013 08:00 ET | Source: Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals Announces Presentation at the Canaccord Genuity Growth Conference

CAMBRIDGE, Mass., Aug. 6, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel...
August 05, 2013 08:00 ET | Source: Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program

CAMBRIDGE, Mass., Aug. 5, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative,...
August 01, 2013 09:50 ET | Source: Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals Receives European Approval for LOJUXTA(TM) (lomitapide) to Treat Homozygous Familial Hypercholesterolemia (HoFH)

CAMBRIDGE, Mass., Aug. 1, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of novel, life-altering...